⌕
Pharming Group · PHAR · Nasdaq
Tenet 41 · Weak
Compare
$12.59−0.08%At closeTenet 41 · Weak
$12.59−0.01 (−0.08%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Pharming Group (PHAR) Stock

Pharming Group (PHAR) closed at $12.59 on Nov 16, 2026; its Tenet Score is 41 of 100 against 409 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

Key stats

Previous close
$12.59
Nov 16, 2026
Market cap
$883.4M
share price × the latest quarter's diluted weighted-average share count (vendor)
P/E
348.4×
price ÷ the latest fiscal year EPS
52-week range
9.11 – 21.34
low → high
Tenet Score
41/100
Weak · 409 Healthcare peers

Industry: Drugs · see every company filed here →

Pharming Group N.V. scores 41/100. Weak. Growth is the soft spot, trading at 348× earnings versus 409 Healthcare peers.

Tenet Score · vs sector

n=409
41/ 100
Weak
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
33
Quality
64
Health
55
Growth
12

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
ValueDQualityCHealthCGrowthFMomentumF
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/B
3.2×
cap ÷ fiscal 2025 book value, Nov 13, 2026 close
P/S
3.6×
price to sales
ROE
1%
fiscal 2025
Operating margin
8.9%
before interest and tax
Net margin
1.0%
fiscal 2025
Current ratio
2.83
fiscal 2025
Net debt / EBITDA
−2.4×Tenet-derived Total debt less cash and short-term investments, over EBITDA (operating income plus depreciation and amortisation) from the filed statements. Long-term investments are not counted as cash. For some companies they include marketable securities held for more than a year. Computed by Tenet from the filed statements (formula house-nde.v1), because the data vendor published no value for this year.
computed by Tenet from the filed statements
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.
Div yield
—
no yield on file

The whole report, at a glance · every card is a live peek, click any to open the section

About Pharming Group N.V.

Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's le…

Composite computed Nov 16, 2026 · peer basis: Healthcare (n=409) · every glimpse links to its full section with sources · not investment advice.

Similar-sized companies in Drugs

The 10 companies in this industry closest in market cap, as of Nov 13, 2026.

What sector and industry is Pharming Group in?

Pharming Group is in the Healthcare sector and the Drugs industry.

What is Pharming Group's Tenet Score?

Pharming Group's Tenet Score is 41 out of 100, ranked against 409 Healthcare peers as of Nov 16, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.